NCT02141919View on ClinicalTrials.gov

Stereotactic Ablative Body Radiation Therapy for Patients With Primary Renal Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

November 30, 2025

Study Completion Date

December 31, 2025

Conditions
Renal Cancers
Interventions
RADIATION

Stereotactic Ablative Radiation Therapy

Stereotactic Ablative Body Radiation Therapy (SABR): 3 fractions of 12Gy, or 4 fractions of 10Gy or 5 fractions of 8 Gy

Trial Locations (1)

75239

University of Texas Southwestern, Dallas

All Listed Sponsors
lead

University of Texas Southwestern Medical Center

OTHER